SGTX Annual CFO
-$51.47 M
+$26.93 M+34.35%
31 December 2022
Summary:
As of January 22, 2025, SGTX annual cash flow from operations is -$51.47 million, with the most recent change of +$26.93 million (+34.35%) on December 31, 2022. During the last 3 years, it has fallen by -$1.40 million (-2.80%).SGTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGTX Quarterly CFO
-$4.16 M
+$7.25 M+63.55%
30 June 2023
Summary:
As of January 22, 2025, SGTX quarterly cash flow from operations is -$4.16 million, with the most recent change of +$7.25 million (+63.55%) on June 30, 2023. Over the past year, it has increased by +$10.63 million (+71.88%).SGTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGTX TTM CFO
-$32.76 M
+$10.63 M+24.49%
30 June 2023
Summary:
As of January 22, 2025, SGTX TTM cash flow from operations is -$32.76 million, with the most recent change of +$10.63 million (+24.49%) on June 30, 2023. Over the past year, it has increased by +$41.25 million (+55.73%).SGTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +34.4% | +71.9% | +55.7% |
| 3 y3 years | -2.8% | +74.5% | -4.0% |
| 5 y5 years | -234.3% | - | - |
SGTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -234.3% | at high | +115.5% |
Sigilon Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$4.16 M(-63.6%) | -$32.76 M(-24.5%) |
| Mar 2023 | - | -$11.40 M(+58.0%) | -$43.39 M(-15.7%) |
| Dec 2022 | -$51.47 M(-34.3%) | -$7.22 M(-27.7%) | -$51.47 M(-16.5%) |
| Sept 2022 | - | -$9.99 M(-32.4%) | -$61.64 M(-16.7%) |
| June 2022 | - | -$14.78 M(-24.2%) | -$74.01 M(-1.6%) |
| Mar 2022 | - | -$19.49 M(+12.1%) | -$75.22 M(-4.1%) |
| Dec 2021 | -$78.41 M | -$17.38 M(-22.3%) | -$78.41 M(+0.3%) |
| Sept 2021 | - | -$22.37 M(+39.9%) | -$78.15 M(+13.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$15.99 M(-29.5%) | -$68.80 M(-0.5%) |
| Mar 2021 | - | -$22.67 M(+32.4%) | -$69.12 M(+12.1%) |
| Dec 2020 | -$61.65 M(+23.1%) | -$17.12 M(+31.6%) | -$61.65 M(+38.5%) |
| Sept 2020 | - | -$13.02 M(-20.2%) | -$44.52 M(+41.3%) |
| June 2020 | - | -$16.31 M(+7.3%) | -$31.51 M(+107.3%) |
| Mar 2020 | - | -$15.20 M | -$15.20 M |
| Dec 2019 | -$50.07 M(-230.6%) | - | - |
| Dec 2018 | $38.33 M | - | - |
FAQ
- What is Sigilon Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Sigilon Therapeutics?
- What is Sigilon Therapeutics annual CFO year-on-year change?
- What is Sigilon Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Sigilon Therapeutics?
- What is Sigilon Therapeutics quarterly CFO year-on-year change?
- What is Sigilon Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Sigilon Therapeutics?
- What is Sigilon Therapeutics TTM CFO year-on-year change?
What is Sigilon Therapeutics annual cash flow from operations?
The current annual CFO of SGTX is -$51.47 M
What is the all time high annual CFO for Sigilon Therapeutics?
Sigilon Therapeutics all-time high annual cash flow from operations is $38.33 M
What is Sigilon Therapeutics annual CFO year-on-year change?
Over the past year, SGTX annual cash flow from operations has changed by +$26.93 M (+34.35%)
What is Sigilon Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SGTX is -$4.16 M
What is the all time high quarterly CFO for Sigilon Therapeutics?
Sigilon Therapeutics all-time high quarterly cash flow from operations is -$4.16 M
What is Sigilon Therapeutics quarterly CFO year-on-year change?
Over the past year, SGTX quarterly cash flow from operations has changed by +$10.63 M (+71.88%)
What is Sigilon Therapeutics TTM cash flow from operations?
The current TTM CFO of SGTX is -$32.76 M
What is the all time high TTM CFO for Sigilon Therapeutics?
Sigilon Therapeutics all-time high TTM cash flow from operations is -$15.20 M
What is Sigilon Therapeutics TTM CFO year-on-year change?
Over the past year, SGTX TTM cash flow from operations has changed by +$41.25 M (+55.73%)